



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
MBHB Case No. 99-130-I

In re Application of:

Tallman, et al.

Serial No.: 10/045,396

Filed: November 9, 2001

For: Methods for Screening GABA-Modulatory
Compounds for Specified Pharmacological
Activities

)

)

)

)

)

)

)

)

)

)

)

Before the Examiner: - Brannock, M.

Art Unit: 1646

Confirmation No. 6851

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references 2-7 cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

United States Patents

1. Ladduwahetty et al., U.S. Patent No. 6,444,666, issued September 3, 2002.

Foreign Patents

2. PCT Patent Application No. WO 98/04559, published February 5, 1999.
3. PCT Patent Application No. WO 98/34923, published August 13, 1998.
4. PCT Patent Application No. WO 98/50384, published November 12, 1998.
5. PCT Patent Application No. WO 99/00391, published January 7, 1999.
6. PCT Patent Application No. WO 99/37303, published July 29, 1999.

Other Documents


7. Whiting, *Current Opinion in Drug Discovery & Dev.* (2003) 6(5):648-657.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

Date: August 4, 2005

By:


Steven J. Sarussi

Reg. No. 32,784

McDonnell, Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 31st Floor
Chicago, IL 60606
312 913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99-130-I

Serial No.

10/045,396



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

Applicant:

Tallman, et al.

Filing Date:

November 9, 2001

Group:

1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	6,444,666	Sept 3, 2002	Ladduwahetty et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	2.	WO 98/04559	Feb 5, 1999	PCT				
	3.	WO 98/34923	Aug 13, 1998	PCT				
	4.	WO 98/50384	Nov 12, 1998	PCT				
	5.	WO 99/00391	Jan 7, 1999	PCT				
	6.	WO 99/37303	July 29, 1999	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	7.	Whiting, <i>Current Opinion in Drug Discovery & Dev.</i> (2003) 6(5):648-657.
EXAMINER		
DATE CONSIDERED		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.